Branded Pharmaceuticals Stocks Q2 In Review: Zoetis (NYSE:ZTS) Vs Peers

Collegium Pharmaceutical (COLL) reported $199.9M revenue, up 6.3% YoY, missing expectations. Its stock fell 38.3%. Eli Lilly (LLY) reported $22.97B revenue, up 47.7%, beating expectations. Its stock rose 5.9%. Supernus Pharmaceuticals (SUPN) reported $211.3M revenue, up 27.7%, exceeding expectations. Its stock fell 4%.

Original reporting
Published Oct 13, 2026, 4:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 4:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Branded Pharmaceuticals Stocks Q2 In Review: Zoetis (NYSE:ZTS) Vs Peers — source image
Decision brief

The 30-second read

$ZTSNeutralLow
01

Why it matters

Because the provided body contains only earnings recap-style details for several companies and no new filings, guidance revisions beyond what is already reported, or sector-wide policy catalysts, the trading value is limited to confirming dispersion across names.

02

Market read

Useful for quick sentiment checks on branded pharma earnings dispersion, but not a fresh catalyst feed for new positions.

03

What to watch

For SUPN and COLL, the body does not explain the magnitude of the market’s reaction beyond stating the stock is up or down, so key drivers (segment mix, pipeline updates, margins, or one-offs) are missing.

Relevance 4/10Novelty 3/10Timing: after Q2 results, as the article summarizes branded-pharma earnings outcomes

Background

The article is a Q2 branded-pharmaceuticals review that summarizes quarterly results for multiple companies and then shifts to a broad market-risk narrative (AI, then geopolitics).

Company-level read

Ticker impact

$ZTSNeutralLow confidence
Context

The title frames a Q2 branded-pharma review pitting Zoetis against peers, but the body text provides no Zoetis-specific results or catalyst.

Expected impact

No clear directional bias from this article text for ZTS.

Evidence & confidence

ZTS is only named in the title; the body discusses other pharma companies’ quarterly figures and a generic market narrative.

$COLLBearishMedium confidence
Context

Collegium Pharmaceutical reported Q2 revenues of $199.9M, up 6.3% YoY, but missed expectations and guided full-year revenue and EBITDA below analysts.

Expected impact

Likely continued downside or underperformance as the market digests weaker-than-expected full-year guidance.

Evidence & confidence

The body includes specific revenue/EPS expectation misses and states full-year revenue and EBITDA guidance missed analysts’ expectations, plus notes the stock is down 38.3% since results.

$LLYBullishMedium confidence
Context

Eli Lilly reported revenues of $22.97B, up 47.7% YoY, beating expectations, and also beat EPS and full-year EPS guidance.

Expected impact

Likely upward bias as the market rewards the beat versus analysts’ expectations and guidance.

Evidence & confidence

The body provides multiple beat metrics (revenue, EPS, and full-year EPS guidance) and notes the stock is up 5.9% since reporting.

$SUPNNeutralLow confidence
Context

Supernus Pharmaceuticals reported Q2 revenues of $211.3M, up 27.7% YoY, beating expectations, and exceeded full-year operating income guidance.

Expected impact

Near-term direction is uncertain; fundamentals are positive but the article notes the stock is down 4% since reporting.

Evidence & confidence

The body includes beat metrics and guidance outperformance, but also states the stock is down, without explaining the divergence.

Market effects

The piece is a branded-pharma earnings snapshot, with guidance misses (COLL) and strong beats (LLY) reinforcing dispersion across specialty pharma.

Primarily US-listed pharma names, with no cross-region policy or macro shock described beyond a generic market narrative.

No direct global linkage beyond broad themes (AI and geopolitics) that are not tied to specific company fundamentals.

Counterpoint

The article is framed as a Q2 review, so the post-earnings price moves may already reflect the market’s reaction; without new guidance changes or fresh filings, incremental trading edge is limited.

Key entities

  • Zoetis

    Named in the title as the comparison anchor, but no Zoetis-specific figures or events appear in the provided body.

  • Collegium Pharmaceutical

    Reports revenue growth but misses expectations and full-year guidance; stock down sharply since results.

  • Eli Lilly

    Strong revenue and EPS beats versus expectations; stock up since reporting.

  • Supernus Pharmaceuticals

    Revenue and operating income guidance beats, but stock is down since reporting.

Related articles

$ROG.SWMedAI 8/10

Roche Secures FDA Approval for Wilserdly in Advanced Breast Cancer Treatment

Roche (RHHBY) received FDA approval for Wilserdly (giredestrant), an oral treatment for advanced breast cancer, in combination with Novartis' Afinitor. The drug is Roche's first US-approved treatment of its kind and could significantly boost future sales. Roche is also awaiting FDA decision for earlier-stage use. Competitors like AstraZeneca (AZN) and Eli Lilly (LLY) are developing similar treatments.

$LLYHighAI 9/10

Lilly agrees to acquire Calytrix Bio for $1.5bn

Eli Lilly (LLY) will acquire Calytrix Bio for up to $1.5bn to advance a biparatopic antibody for myeloproliferative neoplasms. The deal includes an upfront payment and milestone-based payouts. Calytrix Bio's therapy targets mutant calreticulin-driven diseases, aiming to modify the disease course. According to Calytrix Bio, the acquisition accelerates their vision to benefit patients.

$LLYMed

TGA registers new GLP-1 pill

The TGA has approved Lilly's GLP-1 pill, Foundayo, for obesity and type 2 diabetes treatment. Lilly expects stock to arrive soon, making it the first GLP-1 pill available in Australia. This follows the TGA's approval of Novo Nordisk's Wegovy tablet.

$LLYMed

Retatrutide Cut Sleep Apnea Breathing Events Up to 60.6% in Lilly Trial, but the Weekly Shot Remains Unapproved

Eli Lilly reported that retatrutide, an experimental weekly injection, reduced breathing interruptions in sleep apnea patients by up to 60.6% in an 80-week trial. The drug also showed a 48.1% reduction in a separate trial involving Type 2 diabetes patients. Lilly plans to seek FDA approval in early 2027, but the drug is not yet approved for any use. The results were presented at ObesityWeek 2026, with full peer-reviewed data not yet published.